Nanobody Conjugates for Targeted Cancer Therapy and Imaging
Wei Kang1,2, Chuanfeng Ding3, Danni Zheng1
1School of Bioengineering, Dalian University of Technology, Dalian, China.
Abstract:
Conventional antibody-based targeted cancer therapy is one of the most promising avenues of successful cancer treatment, with the potential to reduce toxic side effects to healthy cells surrounding tumor cells. However, the full potential of antibodies is severely limited due to their large size, low stability, slow clearance, and high immunogenicity. Alternatively, recently discovered nanobodies, which are the smallest naturally occurring antigen-binding format, have shown great potential for addressing these limitations. Bioconjugation of nanobodies to functional groups such as toxins, enzymes, radionucleotides, and fluorophores can improve the efficacy and potency of nanobodies, enhance their in vivo pharmacokinetics, and expand the range of potential applications. Herein, we review the superior characteristics of nanobodies in comparison to conventional antibodies and provide insight into recent developments in nanobody conjugates for targeted cancer therapy and imaging.
Insights
Nanobodies offer a promising alternative to conventional antibodies for targeted cancer therapy due to their small size and enhanced properties. Bioconjugation further improves their efficacy for cancer treatment and imaging applications.
Area of Science:
- Biotechnology
- Immunology
- Oncology
Background:
- Conventional antibody-based cancer therapies show promise but are limited by antibody size, stability, and immunogenicity.
- Nanobodies, the smallest antigen-binding proteins, present a potential solution to these limitations.
Purpose of the Study:
- To review the advantages of nanobodies over conventional antibodies.
- To explore recent advancements in nanobody conjugates for cancer therapy and imaging.
Main Methods:
- Comparative analysis of nanobody and antibody characteristics.
- Review of literature on nanobody bioconjugation techniques.
- Examination of nanobody applications in targeted cancer therapy and imaging.
Main Results:
- Nanobodies exhibit superior properties including smaller size, better stability, and lower immunogenicity compared to conventional antibodies.
- Bioconjugation of nanobodies enhances their efficacy, pharmacokinetics, and expands their therapeutic and diagnostic potential.
- Recent developments show significant progress in nanobody conjugates for targeted cancer treatment and imaging.
Conclusions:
- Nanobodies represent a significant advancement over conventional antibodies for targeted cancer therapy.
- Nanobody conjugates offer improved efficacy and versatility for cancer treatment and diagnostic imaging.
More Related Videos
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
10:47Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging
Published on: February 3, 2015
